IRAK4 PROTAC Degraders for Kinase–Scaffold Protein Targeting
Solution Overview
Problem
Existing IRAK4 inhibitors face challenges in effectively targeting and degrading IRAK4, leading to drug resistance and insufficient therapeutic effects on immunological and inflammatory diseases due to IRAK4's dual function as a kinase and scaffold protein.
Innovation Solution
Development of IRAK4 degraders using PROTAC technology, which utilizes a bifunctional molecule to ubiquitinate and degrade IRAK4, overcoming drug resistance by directly targeting the protein for degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule inhibitors are used to inhibit IRAK4 kinase activity, then kinase activity is suppressed, but drug resistance develops and therapeutic effect is insufficient due to IRAK4's dual function as kinase and scaffold protein
Solution Approach 1:
The patent extracts the scaffold protein function from the kinase function by using PROTAC technology to specifically target and degrade IRAK4 protein levels, rather than just inhibiting its kinase activity. This separates the two functions and addresses the limitation of traditional inhibitors that can only suppress kinase activity without eliminating the scaffold function.
Solution Approach 2:
The patent introduces an intermediary molecule (PROTAC) that mediates between the inhibitor and the target protein. The PROTAC molecule binds to both the E3 ubiquitin ligase and IRAK4, forming a ternary complex that recruits the proteasome to degrade IRAK4, thereby achieving protein degradation rather than simple inhibition.
2Reliability
If PROTAC technology is used to degrade IRAK4, then therapeutic efficacy is improved, but device complexity increases due to the bifunctional molecule structure
Solution Approach 1:
The patent segments the PROTAC molecule into distinct functional modules: a VHL ligand segment that binds to the E3 ubiquitin ligase, a linking chain segment, and an IRAK4 binder segment. This segmentation allows each part to perform its specific function while maintaining overall molecular feasibility and reducing synthesis complexity.
Solution Approach 2:
The patent employs a universal PROTAC platform approach where the same basic PROTAC structure can be adapted to target different proteins by changing the ligand and binder segments. This multi-functionality reduces the need to develop entirely new molecules for different targets, thereby reducing overall complexity.
3Quantity of substance
If PROTAC molecules are used to achieve catalytic degradation effect, then dose requirement is reduced, but manufacturing precision requirements increase
Solution Approach 1:
The patent applies partial action by designing PROTAC molecules that achieve sufficient degradation effect at low doses through catalytic mechanism, rather than requiring high doses to achieve the same effect. The bifunctional structure enables a single molecule to catalyze multiple degradation events, reducing the quantity of substance needed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IRAK4 degraders effectively reduce IRAK4 expression, providing therapeutic benefits for a wide range of immunological and inflammatory diseases, including rheumatoid arthritis, atopic dermatitis, and psoriasis, with potential for improved treatment efficacy.
Implementation Method 1
a bifunctional molecule to ubiquitinate and degrade IRAK4
Implementation Method 2
The target protein is then ubiquitinated and degraded via the ubiquitin-proteasome pathway in vivo
Data Source
Figure 1A~1B
Figure 2~3
Figure 4~6A
AI summary
The present invention relates to use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and/or preventing an inflammatory or immune disease. The present invention relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and/or preventing diseases such as rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, vitiligo, dermatomyositis, alopecia areata, urticaria, multiple myositis, an interstitial lung disease, systemic lupus erythematosus, systemic sclerosis, and psoriasis.